KalVista Pharmaceuticals, Inc. (KALV) on Monday announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted marketing and manufacturing approval for Ekterly for the treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
KalVista said kterly will be commercialized in Japan by KalVista's partner, Kaken Pharmaceutical Co., Ltd., which plans to launch the treatment shortly after it is listed on Japan's National Health Insurance (NHI) system.
Ekterly has received seven regulatory approvals across major global markets, including the United States, United Kingdom, European Union, Switzerland, Australia, Singapore, and Japan, for treating HAE attacks in individuals aged 12 and older.
KalVista Pharma shares closed at $15.23, up 1.53% on Friday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.